Hims and Hers Health is planning to cash in on Novo Nordisk losing its semaglutide drug exclusivity in Canada. The telehealth ...

Hims & Hers Health announced plans to expand to Canada in 2026. Hims will offer generic copies of semaglutide drugs in Canada ...

The Hims & Hers wellness platform announced Wednesday it will soon offer a generic version of the weight loss drug ...

Hims & Hers Health (NYSE:HIMS) stock gains as the company eyes Canada expansion to offer affordable versions of Novo ...

The move follows a dramatic breakup in June between Hims & Hers and Danish drug maker Novo Nordisk, which makes the brand name weight loss drug Wegovy. Novo Nordisk accused the Hims & Hers of ...

Danish pharmaceutical giant Novo Nordisk is set to lose Canadian patent protection on its popular semaglutide-based drugs, ...

Hims & Hers announced plans to expand its weight loss program to Canada in 2026 in connection with the availability of generic semaglutide anywhere in the world.

U.S. telehealth platform looks to take advantage of Ozempic patent expiring in January, while four manufacturers filed for ...

Market Catalysts host Julie Hyman tracks today's top moving stocks and biggest market stories in this Market Minute. Nvidia ...

The number of reported measles cases in the United States has hit 1,288 in the first six months of this year, the most since ...

Parkinson's disease occurs when brain cells that produce an important hormone called dopamine begin to die off or become ...